The Federal Trade Commission took action Friday against the nation’s three largest pharmacy benefit managers, accusing the companies of artificially inflating insulin list prices that resulted in ...

As retail investors flock to Viking Therapeutics, the biotech firm is also catching the eye of billionaire fund managers like ...

We recently published a list of 10 Worst Booming Stocks to Buy According to Short Sellers. In this article, we are going to ...

In January, a new Idaho law will take effect requiring reform of business practices by pharmacy middlemen — in search of ...

The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...